LY2940680 + LY2940680
Phase 1Withdrawn 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Medulloblastoma, Childhood
Conditions
Medulloblastoma, Childhood, Rhabdomyosarcoma
Trial Timeline
Jul 1, 2013 → Jul 1, 2016
NCT ID
NCT01697514About LY2940680 + LY2940680
LY2940680 + LY2940680 is a phase 1 stage product being developed by Eli Lilly for Medulloblastoma, Childhood. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01697514. Target conditions include Medulloblastoma, Childhood, Rhabdomyosarcoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01697514 | Phase 1 | Withdrawn |
Competing Products
9 competing products in Medulloblastoma, Childhood
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LDE225 + TMZ | Novartis | Phase 2 | 52 |
| LDE225 | Novartis | Phase 1/2 | 41 |
| Lomustine + Vincristine + Cisplatin + Cyclophosphamide + Mesna + Vincristine | Brain Biotech | Phase 1 | 25 |
| Modified Measles Virus + Modified Measles Virus Lumbar Puncture | Brain Biotech | Phase 1 | 25 |
| CX 4945 | Brain Biotech | Phase 1/2 | 33 |
| SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years + SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years + SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years | Brain Biotech | Phase 1 | 25 |
| PEP-CMV | Brain Biotech | Phase 1 | 25 |
| Apatinib Combined With Temozolomide and Etoposide Capsules | Brain Biotech | Phase 2 | 44 |
| Irinotecan + Temozolomide + Bevacizumab + Omburtamab I-131 + Liothyronine + SSKI + Dexamethasone + Antipyretic + Antihistamine + anti-emetics | Brain Biotech | Phase 2 | 44 |